Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling

Marie Will¹⁴, Alice Can Ran Qin¹, Weiyi Toy², Zhan Yao¹, Vanessa Rodrik-Outmezguine¹, Claudia Schneider⁵, Xiaodong Huang¹, Prashant Monian³, Xuejun Jiang³, Elisa de Stanchina¹, José Baselga², Ningshu Liu⁵, Sarat Chandarlapaty¹⁴, and Neal Rosen¹⁴
ABSTRACT

The effects of selective phosphoinositide 3-kinase (PI3K) and AKT inhibitors were compared in human tumor cell lines in which the pathway is dysregulated. Both caused inhibition of AKT, relief of feedback inhibition of receptor tyrosine kinases, and growth arrest. However, only the PI3K inhibitors caused rapid induction of cell death. In seeking a mechanism for this phenomenon, we found that PI3K inhibition, but not AKT inhibition, causes rapid inhibition of wild-type RAS and of RAF–MEK–ERK signaling. Inhibition of RAS–ERK signaling is transient, rebounding a few hours after drug addition, and is required for rapid induction of apoptosis. Combined MEK and AKT inhibition also promotes cell death, and in murine models of HER2+ cancer, either pulsatile PI3K inhibition or combined MEK and AKT inhibition causes tumor regression. We conclude that PI3K is upstream of RAS and AKT and that pulsatile inhibition of both pathways is sufficient for effective antitumor activity.

SIGNIFICANCE: We show that the RAS–ERK pathway is a key downstream effector pathway of oncogenic PI3K. Coordinate downregulation of AKT and ERK is necessary for induction of apoptosis and antitumor activity and can be accomplished with pulsatile dosing, which will likely decrease toxicity and allow administration of therapeutic doses. Cancer Discov; 4(3); 1–14. © 2014 AACR.

INTRODUCTION

The PI3K–AKT–mTOR signaling pathway is frequently activated in cancer, deregulates control of metabolism, cell proliferation, and apoptosis, and is required for the initiation and maintenance of transformation in model systems. Hyperactivation of this pathway is associated with exaggerated physiologic feedback inhibition of many components of the signaling network, the consequences of which include marked downregulation of multiple receptors and their ability to signal.

Many components of this pathway have been shown to be mutated or otherwise dysregulated in tumors (1–5). Mechanisms of activation include amplification or mutation of receptors that entrain phosphoinositide 3-kinase (PI3K) signaling, especially HER2 and HER3, mutation or amplification of the genes encoding the catalytic or regulatory subunits of class I PI3Ks, prominently PIK3CA, and loss-of-function mutations of genes that encode negative regulators of the pathway, such as PTEN, INPP4B, TSC, and LKB1. Such mutations are very common in endometrial, prostate, breast, colorectal, and other cancers. In some cancers (colorectal cancer and melanoma), they often coexist with mutations in RAS or RAF that activate the RAS–ERK signaling pathway; in other cancers (breast, prostate), they do not.

The prevalence of activation of PI3K signaling in tumors has led to the development of inhibitors of several components of the pathway, including the PI3K, AKT, mTOR kinases, and Rapamycin analogs that inhibit mTORC1. Experimental models of tumors with dysregulated activation of the pathway, especially those with PIK3CA mutation or HER2 amplification, tend to be selectively sensitive to inhibitors of AKT or PI3Kα if they do not have coexisting mutations in RAS or RAF (6). In contrast, sensitivity to mTOR inhibitors is less genotype specific, and most tumor cell lines tend to be at least somewhat sensitive to these drugs.

Despite the sensitivity of tumor models to both genetic and pharmacologic inhibition of the pathway, the therapeutic efficacy of these inhibitors has been marginal. This may be due in part to the use of unselective drugs that do not inhibit the pathway effectively because off-target toxicities limit dosing. In addition, mTOR and AKT inhibitors relieve feedback inhibition of receptor signaling and activate PI3K, ERK, and other effectors (7–10). Reactivation of upstream signaling may attenuate or even prevent the antitumor activity of these drugs. Inhibition of AKT reactivates receptor signaling (by inhibiting mTOR/S6 kinase) and receptor expression (by activating FOXO-dependent expression of HER3 and IGF/insulin receptors), thereby inducing PI3K and ERK activation. Inhibition of mTORC1 similarly reactivates receptor, PI3K, and ERK signaling, but also activates AKT, thus enforcing FOXO inhibition, and receptor expression is not induced. Thus, the effects of inhibitors of different components of the pathway differ both in the spectrum of substrates they suppress and in the details of their effects of feedback. However, both mTOR and AKT inhibitors activate receptor signaling, PI3K activity, and ERK signaling.

Because mTOR and AKT inhibitors reactivate PI3K signaling, we asked whether PI3K inhibitors have more significant antitumor activity, perhaps by inhibiting other PI3K targets in addition to AKT–mTOR. Selective PI3K and AKT inhibitors were compared in tumors with activation of PI3K pathway signaling to assess differences in the biochemical and biologic consequences of their inhibition. Both inhibitors effectively inhibited downstream targets of AKT, relieved feedback inhibition of growth factor receptors, and inhibited cell growth. However, in HER2-dependent breast cancers,
PI3K inhibitors, but not AKT inhibitors, caused the rapid induction of a significant degree of apoptosis. We find that whereas AKT inhibitors inhibit AKT–mTOR and activate ERK signaling, PI3K inhibitors inhibit both. They cause not only durable inhibition of AKT signaling but also transient inhibition of RAS activation and ERK signaling, both of which are required for induction of apoptosis. Moreover, induction of apoptosis by an AKT inhibitor is significantly enhanced when combined with an MEK inhibitor. Our results show that PI3K is upstream of wild-type RAS as well as AKT–mTOR, and this causes the therapeutic consequences of PI3K inhibition to be significantly greater than those of AKT inhibition.

RESULTS

AKT and PI3K inhibitors both inhibit AKT–mTOR signaling but AKT and mTOR inhibitors activate (8, 10), whereas PI3K inhibitors inhibit, PI3K activity. To examine the different biochemical and biologic consequences of inhibiting these two nodes of the pathway, we compared the effects of the AKT inhibitor MK2206 with those of the PI3K inhibitor BAY 80-6946. MK2206 is a highly selective, allostERIC inhibitor of AKT 1, 2, and 3 that inhibits the phosphorylation of these kinases by preventing their association with the membrane (6, 11). BAY 80-6946 (chemical structure depicted in Supplementary Fig. S1A) is an ATP-competitive selective inhibitor of class I PI3Ks, more potent against PI3Kα (IC₅₀ = 0.5 nmol/L) and PI3Kβ (IC₅₀ = 0.7 nmol/L) than PI3Kβ (IC₅₀ = 3.7 nmol/L) and PI3Kγ (IC₅₀ = 6.4 nmol/L), and much less active against mTOR (IC₅₀ = 45 nmol/L) and other PIks (no inhibition at 1 μmol/L; ref. 12). After 1 hour of exposure of the HER2-amplified breast cancer cell line BT-474 to 50 nmol/L BAY 80-6946, the phosphorylation of AKT, its substrates such as PRAS40 and MDM2, as well as downstream effectors such as S6 and 4E-BP1, are potently inhibited by the compound (Supplementary Fig. S1B). To identify a dose range in which BAY 80-6946 inhibits PI3K but not mTOR, we utilized LAM TSC2+/−, a cell line in which mTOR signaling is not dependent upon AKT activation (Supplementary Fig. S1C). In this model, after 3 hours of treatment, the mTOR kinase inhibitor AZD8055 blocked the phosphorylation of mTOR substrates and their targets (4E-BP1 and S6), whereas MK2206 blocked the phosphorylation of AKT but not that of mTOR substrates. Treatment with doses of BAY 80-6946 ranging from 10 to 250 nmol/L blocked the phosphorylation of AKT S473 and PRAS40 T246, but did not affect the phosphorylation of mTOR targets. Above 500 nmol/L, BAY 80-6946 blocked both AKT and mTOR substrates. Thus, at doses of 250 nmol/L and below, BAY 80-6946 selectively inhibits PI3Ks and not mTOR in cells.

Selective doses of BAY 80-6946 (50 nmol/L) and MK2206 (2 μmol/L) were used to compare the effects of PI3K and AKT inhibition in BT-474 cells, a breast tumor model with HER2 amplification and PIK3CA mutation that is dependent on AKT for proliferation (6, 8). Both drugs rapidly inhibited the phosphorylation of AKT (S473, T308) as well as its direct substrates PRAS40 (T246) and GSK3β (S9), and inhibition was sustained for up to 24 hours (Fig. 1A). Despite these similarities in modulating AKT signaling, there was a marked difference in induction of apoptosis, as assessed by the appearance of cleaved caspases 3 and 7. Compared with AKT inhibition, PI3K inhibition led to significantly more cleaved caspase beginning at 30 minutes after drug exposure and persisting for up to 24 hours. Similar results were obtained with another HER2-amplified, PIK3CA-mutant tumor model, MDA-MB-361 (Supplementary Fig. S1D). These findings suggested a major difference in the biologic consequences of PI3K and AKT inhibition.

We have previously reported that breast cancer models with PIK3CA mutation or HER2 amplification are sensitive to AKT inhibition. In these tumors, inhibiting AKT reduces cyclin D expression and causes growth arrest in the G1 phase of the cell cycle (6). Apoptosis is modest and occurs later, 48 to 72 hours after drug addition. BAY 80-6946 had similar effects on cell proliferation and the accumulation of cells in G1 (Fig. 1B and Supplementary Fig. S1E and S1F). However, whereas AKT inhibition was associated with a slight increase in cell number followed by cessation of growth (Fig. 1C), PI3K inhibition caused significant apoptosis (Fig. 1B and Supplementary Fig. S1E and S1F) and a 33.5% reduction in cell number by 72 hours after drug exposure (Fig. 1C). The apoptotic process was induced rapidly after PI3K inhibition. Cleaved caspase-3, caspase-7, and PARP were detected within 30 minutes of PI3K inhibition (Fig. 1A and D), reached a peak by 2 hours, and persisted for at least 24 hours after drug exposure. In contrast, AKT inhibition caused only a modest induction of caspase cleavage 2 hours after drug exposure, which then fell to trace levels at 4 hours, and modest induction in the fraction of sub-G1 DNA at 72 hours after MK2206 addition (Fig. 1A and B). Enhanced induction of apoptosis with PI3K inhibition as compared with AKT inhibition was also noted in two other HER2-amplified breast cancer models, SK-BR-3 and MDA-MB-361 (Supplementary Fig. S1E and S1F).

To determine whether induction of caspase cleavage was due to activation of the intrinsic apoptotic pathway, BT-474 cells were engineered to express high levels of BCL-XL. BCL-XL overexpression did not alter inhibition of PI3K signaling by BAY 80-6946 (Fig. 1D). However, the accumulation of cleaved caspase-3, cleaved caspase-7, and cleaved PARP that was evident in untransfected and vector-transfected BT-474 cells was completely suppressed by overexpression of BCL-XL. PI3K inhibition did suppress the proliferation of these cells, but it did not reduce their viability, as it did in control cells (Fig. 1E). In fact, the response of BCL-XL-overexpressing cells to BAY 80-6946 resembled the response of untransfected BT-474 to the AKT inhibitor (Fig. 1C and E). We conclude that, although PI3K and AKT inhibitors inhibit AKT signaling to an equivalent degree, PI3K inhibition induces significantly more apoptosis and does so very rapidly.

We attempted to determine the basis for the differential effects of PI3K and AKT inhibition on cell viability (Fig. 2A and Supplementary Fig. S2A). Substrates of AKT kinases such as PRAS40, GSK3β, and FOXO were inhibited similarly by both drugs. Targets of mTOR such as p56 and p4EBP1 were also inhibited by both, although PI3K inhibition blocked 4E-BP1 phosphorylation more potently and longer than AKT inhibition (Fig. 2A and Supplementary Fig. S2A). Activation of PI3K–AKT–mTOR signaling has been shown to cause feedback inhibition of multiple components of the signaling network, including the expression and activity of...
Figure 1. PI3K inhibition induces more apoptosis than AKT inhibition. **A**, BT-474 cells were treated with BAY 80-6946 (50 nmol/L) or MK2206 (2 μmol/L) and collected at indicated times. Immunoblots of AKT, AKT substrates, and surrogates for apoptosis show similar AKT inhibition but greater apoptosis with PI3K inhibition. **B**, cell-cycle distribution of BT-474 cells treated with dimethyl sulfoxide (DMSO), MK2206 (2 μmol/L), or BAY 80-6946 (50 nmol/L) for 24, 48, or 72 hours as determined by fluorescence-activated cell sorting (FACS) analysis shows drugs causing similar suppression of S-phase distribution. Apoptosis results were reported as mean percent sub-G₁ fraction with SEs and show greater %sub-G₁ with PI3K inhibition. **C**, BT-474 cells were treated with DMSO, MK2206 (2 μmol/L), or BAY 80-6946 (50 nmol/L) and viable cells were counted at indicated times, demonstrating loss in viable cell number with PI3K inhibition. Results were reported as a mean of triplicate with SEs. **D**, BT-474 cells untransfected or stably transfected with either pQCXIP vector or pQCXIP–BCL-X<sub>L</sub> were treated with BAY 80-6946 (50 nmol/L) and collected at indicated times. Immunoblots show BCL-X<sub>L</sub> overexpression abolishes the induction of cleaved caspase-3, cleaved caspase-7, and cleaved PARP. **E**, BT-474 cells stably transfected with pQCXIP vector or pQCXIP–BCL-X<sub>L</sub> and treated with DMSO or BAY 80-6946 (50 nmol/L) show that the decrease in viable cells by BAY 80-6946 is blocked by BCL-X<sub>L</sub> overexpression.
receptors that are important activators of PI3K (8–10). AKT and mTOR inhibitors relieve this feedback and reactivate receptor signaling. Differential induction of any of these receptors could result in altered cell survival. We found that the expression and phosphorylation of HER3, IGF-IR, and IR were induced to a similar degree and with similar kinetics by both drugs. Induction of HER3 expression and phosphorylation in cells treated with AKT inhibitors has also been shown to be associated with induction of HER3 heterodimerization with other HER kinases and a reciprocal decrease in HER2 and EGFR phosphorylation (8). This occurred with similar kinetics in cells treated with the PI3K or the AKT inhibitor.

Activation of receptor signaling in cells exposed to AKT or mTOR inhibitors activates PI3K as well as parallel pathways (13). We found that STAT3 phosphorylation was induced by both drugs with the same kinetics, albeit to a slightly greater degree by PI3K inhibition (Fig. 2A). We and others have also shown that AKT or mTOR inhibition causes activation of ERK signaling (7, 14) as shown in Fig. 2C. In contrast, we found that selective inhibition of PI3K with BAY 80-6946 inhibited the phosphorylation of ERK in BT-474 cells (Fig. 2A). Inhibition was rapid and began within 10 minutes after drug exposure, concomitant with inhibition of AKT phosphorylation (Fig. 2B). ERK phosphorylation reached a nadir in 30 minutes and began to rebound in 50 minutes (Fig. 2B). In contrast, there was no decline in phospho-ERK (pERK) in dimethyl sulfoxide (DMSO)-treated control cells (Supplementary Fig. S2B), in cells treated with the AKT inhibitor (MK2206; Fig. 2A and C), a selective mTOR kinase inhibitor (AZD8055; Fig. 2D), or the mTORC1 inhibitor Rapamycin (Supplementary Fig. S2C). These results were not peculiar to BAY 80-6946 or to the BT-474 model. Another selective class I PI3K inhibitor (GDC-0941) also rapidly inhibited ERK signaling, in this case in the PTEN-null, triple-negative breast cancer cell line MDA-MB-468 (Supplementary Fig. S3). Thus, the data suggest that in some cells, ERK activation is dependent on PI3K, but not AKT or mTOR activity.

Recently, it has become clear that PI3K signaling is PI3K isoform dominant in many neoplasms, as a function of both mechanism of pathway activation (PI3Kα when the pathway is activated by receptor tyrosine kinases (RTK); PI3Kβ in PTEN-mutant tumors; refs. 15–17) and lineage (PI3Kα in B-cell lymphomas; refs. 18, 19). We found that downregulation of pERK by PI3K inhibition was not specific for a particular...
class I isoform (Fig. 3A). BYL-719, a PI3Kα-selective inhibitor; GSK2311418A, a PI3Kβ-specific inhibitor; and CAL101, a PI3Kδ-specific inhibitor, all rapidly reduced pERK in models driven by the isoforms they target (for PI3Kα, BT-474; a HER2-amplified, PIK3CA-mutant breast cancer; for PI3Kβ, MDA-MB-468, a PTEN-deficient breast cancer; for PI3Kδ, CCRF-SB, an acute lymphoblastic leukemia cell line). In all three tumor models, the isoform-selective inhibitors caused rapid loss of both AKT and ERK phosphorylation within 15 minutes of drug administration. In each case, there were concomitant decreases of MEK phosphorylation and CRAF S338 phosphorylation. These data suggest that PI3K affects ERK activation by inhibiting RAF activity.

Thus, a variety of selective inhibitors of class I PI3Ks suppresses ERK signaling. To determine whether selective genetic inhibition of the pathway had a similar effect, we utilized an MDA-MB-468 cell line engineered to express wild-type PTEN and induced PTEN expression in a panel of tumor cell lines to assess the generality of this phenomenon (Fig. 4). Downregulation occurred in the majority (16 of 23) of cell lines, including those with HER2 amplification, PIK3CA mutation, or PTEN or INPP4B deficiency, as well as some cell lines without known mechanisms for activation of the pathway. Inhibition of ERK phosphorylation was rapid and rebounded quickly in most tumors, but was more long lasting in some, including the B-cell malignancies. In contrast, in seven cell lines, ERK phosphorylation was insensitive to PI3K inhibition, despite marked inhibition of AKT. These include all four cell lines with RAS mutations. In HCT116, a cell line with a catalytic domain mutation in PIK3CA and an activating mutation in KRAS, PI3K inhibition downregulated pAKT without decreasing ERK, MEK, or CRAF phosphorylation (Supplementary Fig. S4).

The observation that the reduction in pERK after PI3K inhibition occurs in a majority of tumors with wild-type RAS, but not in those with mutant RAS, suggests that it may be due to direct inhibition of wild-type RAS activity. This possibility is supported by the rapidity with which it occurs and the coincident decline in MEK and RAF phosphorylation in all tested cells, including the HER2-amplified breast tumors SK-BR-3 and BT-474 (Fig. 5A). We therefore utilized pull-downs of the RAF1 RAS-binding domain (RBD) to assess levels of the active GTP-bound form of RAS. We found that, in all four cell lines tested, SK-BR-3, BT-474 (Fig. 5A), the lung cancer cell line NCI-H292 (Supplementary Fig. S5A), and
the lymphoma cell line CCRF-SB (Supplementary Fig. S5B), the PI3K inhibitor caused a rapid and marked decline in RAS-GTP within 15 minutes of drug addition. The decline occurred in all three RAS isoforms and was coincident with the decline in pAKT as well as the decline in pERK, pMEK, and p338 CRAF (Fig. 5A). RAS-GTP was also inhibited by another PI3K inhibitor (BAY-719) in BT-474 (Supplementary Fig. S5C). In contrast, the AKT inhibitor reduced AKT phosphorylation, but not the level of RAS-GTP (Fig. 5B). Stimulation with EGF for 5 minutes induced pERK, pMEK, pCRAF, and RAS-GTP levels, whereas inhibition of HER receptor signaling with lapatinib potently blocked pERK, pMEK, and pCRAF, and also inhibited RAS-GTP (Fig. 5B).

RAS-GTP levels rebounded with variable kinetics in the four cell lines, 30 to 240 minutes after exposure of cells to the PI3K inhibitor (Fig. 5A and Supplementary Fig. S5A and S5B). In each of the four cell lines, ERK phosphorylation fell at the same time and then rebounded with the same kinetics as RAS-GTP. These results strongly suggest that PI3K inhibitors transiently suppress the activation of wild-type RAS in tumors in a PI3K-dependent, AKT-independent manner and that this is responsible for the transient ERK inhibition caused by these drugs. Consistent with this model, in tumors with mutant RAS (HCT116, A549), in which the PI3K inhibitor had no effect on ERK phosphorylation, it also had no effect on RAS-GTP levels, but did inhibit AKT phosphorylation (Supplementary Fig. S5D and S5E).

To determine whether mutant RAS is insensitive to PI3K inhibition, we expressed a FLAG-tagged Q61K-mutant NRAS in SK-BR-3 cells in a doxycycline-inducible manner (Fig. 5C). In the absence of doxycycline, the PI3K inhibitor BAY 80-6946 potently and rapidly inhibited RAS-GTP and pERK in these cells. After doxycycline induction, mutant NRAS was expressed in these cells and both mutant and wild-type RAS were bound to GTP. Addition of BAY 80-6946 had no effect on levels of GTP bound to mutant NRAS or levels of

Figure 4. PI3K regulates ERK signaling in many tumor models. Cell lines with indicated tumor genotype were treated with BAY 80-6946 (50 nmol/L) and collected at indicated times. Immunoblots show downregulation of pAKT in all cell lines and loss of pERK in the majority of RAS wild-type cells. NSCLC, non-small cell lung cancer.

<table>
<thead>
<tr>
<th>pAKT (S473)</th>
<th>AKT</th>
<th>pERK (T202/Y204)</th>
<th>ERK</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>SK-BR-3 Breast, HER2 amp</td>
<td>SK-BR-3 Breast, HER2 amp</td>
<td>SK-BR-3 Breast, HER2 amp</td>
<td></td>
</tr>
<tr>
<td>BT-474 Breast, HER2 amp, PIK3CA K111N</td>
<td>BT-474 Breast, HER2 amp, PIK3CA K111N</td>
<td>BT-474 Breast, HER2 amp, PIK3CA K111N</td>
<td></td>
</tr>
<tr>
<td>UACC-893 Breast, HER2 amp, PIK3CA H1047R</td>
<td>UACC-893 Breast, HER2 amp, PIK3CA H1047R</td>
<td>UACC-893 Breast, HER2 amp, PIK3CA H1047R</td>
<td></td>
</tr>
<tr>
<td>HCC1954 Breast, HER2 amp, PIK3CA H1047R</td>
<td>HCC1954 Breast, HER2 amp, PIK3CA H1047R</td>
<td>HCC1954 Breast, HER2 amp, PIK3CA H1047R</td>
<td></td>
</tr>
<tr>
<td>MDA-MB-453 Breast, HER2 amp, PIK3CA H1047R</td>
<td>MDA-MB-453 Breast, HER2 amp, PIK3CA H1047R</td>
<td>MDA-MB-453 Breast, HER2 amp, PIK3CA H1047R</td>
<td></td>
</tr>
<tr>
<td>MDA-MB-361 Breast, HER2 amp, PIK3CA E545K</td>
<td>MDA-MB-361 Breast, HER2 amp, PIK3CA E545K</td>
<td>MDA-MB-361 Breast, HER2 amp, PIK3CA E545K</td>
<td></td>
</tr>
<tr>
<td>MCF-7 Breast, PIK3CA E545K</td>
<td>MCF-7 Breast, PIK3CA E545K</td>
<td>MCF-7 Breast, PIK3CA E545K</td>
<td></td>
</tr>
<tr>
<td>T-47D Breast, PIK3CA H1047R</td>
<td>T-47D Breast, PIK3CA H1047R</td>
<td>T-47D Breast, PIK3CA H1047R</td>
<td></td>
</tr>
<tr>
<td>HCC1806 Breast, INPP4B D647E</td>
<td>HCC1806 Breast, INPP4B D647E</td>
<td>HCC1806 Breast, INPP4B D647E</td>
<td></td>
</tr>
<tr>
<td>NCI-H292 NSCLC</td>
<td>NCI-H292 NSCLC</td>
<td>NCI-H292 NSCLC</td>
<td></td>
</tr>
<tr>
<td>NCI-H1650 NSCLC, PTEN-null, EGFR E746-A750 del</td>
<td>NCI-H1650 NSCLC, PTEN-null, EGFR E746-A750 del</td>
<td>NCI-H1650 NSCLC, PTEN-null, EGFR E746-A750 del</td>
<td></td>
</tr>
<tr>
<td>CCRF-SB Acute myeloid leukemia</td>
<td>CCRF-SB Acute myeloid leukemia</td>
<td>CCRF-SB Acute myeloid leukemia</td>
<td></td>
</tr>
<tr>
<td>U937 Histiocytic lymphoma</td>
<td>U937 Histiocytic lymphoma</td>
<td>U937 Histiocytic lymphoma</td>
<td></td>
</tr>
<tr>
<td>SU-DHL-4 Diffuse large B-cell lymphoma</td>
<td>SU-DHL-4 Diffuse large B-cell lymphoma</td>
<td>SU-DHL-4 Diffuse large B-cell lymphoma</td>
<td></td>
</tr>
<tr>
<td>SU-DHL-5 Diffuse large B-cell lymphoma</td>
<td>SU-DHL-5 Diffuse large B-cell lymphoma</td>
<td>SU-DHL-5 Diffuse large B-cell lymphoma</td>
<td></td>
</tr>
<tr>
<td>A549 NSCLC, KRAS G12S</td>
<td>A549 NSCLC, KRAS G12S</td>
<td>A549 NSCLC, KRAS G12S</td>
<td></td>
</tr>
<tr>
<td>SK-MEL-30 Melanoma, NRAS Q61K</td>
<td>SK-MEL-30 Melanoma, NRAS Q61K</td>
<td>SK-MEL-30 Melanoma, NRAS Q61K</td>
<td></td>
</tr>
<tr>
<td>SK-MEL-2 Melanoma, NRAS Q61K</td>
<td>SK-MEL-2 Melanoma, NRAS Q61K</td>
<td>SK-MEL-2 Melanoma, NRAS Q61K</td>
<td></td>
</tr>
<tr>
<td>NCI-H1703 NSCLC, PDGFRA amp</td>
<td>NCI-H1703 NSCLC, PDGFRA amp</td>
<td>NCI-H1703 NSCLC, PDGFRA amp</td>
<td></td>
</tr>
<tr>
<td>NCI-H661 NSCLC, PDGFRA amp</td>
<td>NCI-H661 NSCLC, PDGFRA amp</td>
<td>NCI-H661 NSCLC, PDGFRA amp</td>
<td></td>
</tr>
<tr>
<td>PC9 NSCLC, EGFR, E746-A750del</td>
<td>PC9 NSCLC, EGFR, E746-A750del</td>
<td>PC9 NSCLC, EGFR, E746-A750del</td>
<td></td>
</tr>
</tbody>
</table>
Figure 5. PI3K regulates the level of active RAS in RAS wild-type cells. A, SK-BR-3 cells (left) or BT-474 cells (right) were treated with BAY 80-6946 (50 nmol/L) and collected at indicated times. RAS-GTP level was assayed by RAF1-RBD pull down (PD) and lysates from the same samples were immunoblotted. PI3K inhibition blocks AKT phosphorylation and causes a loss of RAS-GTP level (total and individual isoforms) corresponding with changes in RAF–MEK–ERK activity. B, SK-BR-3 cells (left) or BT-474 cells (right) were treated with BAY 80-6946 (50 nmol/L) or MK2206 (2 μmol/L) for 30 minutes, EGF (100 ng/mL) for 5 minutes, lapatinib (2 μmol/L) for 1 hour, or left untreated, and collected for RAS-GTP analysis (as in A) or immunoblotting. Treatment with EGF activates RAS and RAF–MEK–ERK, whereas RAS–ERK signaling is inhibited by RTK or PI3K inhibition but not AKT inhibition. C, SK-BR-3 cells stably transfected with TTIp-MLUEX-NRAS Q61K were pretreated for 24 hours with doxycycline (1 μg/mL) to induce the expression of exogenous NRAS Q61K (right) or not pretreated (left) before the addition of the PI3K inhibitor BAY 80-6946 (50 nmol/L) for indicated times, EGF (100 ng/mL) for 5 minutes, or lapatinib (2 μmol/L) for 1 hour. RAS-GTP analysis was performed as in A, and lysates were immunoblotted. PI3K inhibition decreases the GTP-bound level of the endogenous wild-type, but not the exogenous mutant, RAS protein. Accordingly, pERK was only decreased in cells without the induction of NRAS Q61K expression. N.S., nonspecific band.
of pERK, although it still decreased levels of GTP bound to wild-type RAS. This finding supports the conclusions that PI3K regulates wild-type RAS activation and that PI3K inhibitors suppress ERK signaling by inhibiting activation of wild-type RAS.

We have identified two early consequences of PI3K inhibition that do not occur with AKT inhibitors: suppression of RAS–RAF–MEK–ERK signaling and significant induction of apoptosis. Both occur within 2 hours of drug administration. We sought to determine whether inhibition of ERK signaling was required for induction of apoptosis. To date, PI3K inhibitors administered alone have had significant antitumor activity in the clinic in only a limited subset of tumors: B-cell lymphomas, tumors with HER2 amplification, and breast cancers with PIK3CA mutations. We asked which members of a small set of breast cancer cell lines underwent significant apoptosis when exposed to BAY 80-6946, as measured by induction of sub-G1 DNA content. In our panel, significant apoptosis at 72 hours was essentially limited to those tumors with HER2 amplification (Supplementary Fig. S6).

We used BT-474, a model that underwent significant apoptosis, to ask whether the downregulation of pERK in tumour cells exposed to PI3K inhibitors was required for induction of early apoptosis. Given the rapid and transient inhibition of ERK, we took a physiologic and pharmacologic approach to the question. In HER2-amplified cells, RAS activation is under the control of HER kinases. We treated BT-474 cells with BAY 80-6946 alone, or together with EGF (Fig. 6A). As expected, PI3K inhibition alone led to a decline in phosphorylation of AKT, the AKT substrate PRAS40, and ERK, while inducing apoptosis, as demonstrated by an increase in the cleaved forms of caspase-3, caspase-7, and PARP (lane 3). When coadministered with EGF, BAY 80-6946 still potently decreased pAKT and its substrate pPRAS40, but pERK was no longer downregulated (lanes 4, 5). Under this condition, apoptosis was significantly abrogated as well. To ensure that the rescue of apoptosis was due to lack of ERK inhibition and not EGF activation of other signaling pathways, we utilized a highly selective inhibitor of the HER kinases, PD6325901 (PD901). PD901 alone inhibited ERK, but not AKT or PRAS40 phosphorylation and did not induce caspase or PARP cleavage (lanes 8, 9). When PD901 was coadministered with BAY 80-6946 and EGF, phosphorylation of AKT and PRAS40 remained inhibited and pERK was now inhibited as well (lanes 6, 7). Restoration of ERK inhibition was associated with restoration of apoptosis, as demonstrated by accumulation of cleaved caspases, and PARP. We conclude from these data that the transient inhibition of ERK caused by PI3K inhibition is required for the rapid induction of apoptosis in these cells.

PI3K and AKT inhibitors both inhibit the growth of HER2-dependent breast cancers, but the latter causes much less cell death. Our model suggests that this is because they elevate rather than inhibit ERK signaling and predicts that combined inhibition of AKT and MEK will cause enhanced apoptosis and have greater antitumor effects compared with AKT inhibition alone. We treated BT-474 cells with the AKT inhibitor MK2206, the MEK inhibitor PD901, or a combination of the two. MK2206 downregulated phosphorylation of AKT and its substrate PRAS40, whereas PD901 downregulated phosphorylation of ERK, and the combination effectively blocked both pathways (Fig. 6B). Two hours after drug administration, combined AKT and MEK inhibition caused a greater degree of induction of cleaved caspase-3 and cleaved caspase-7 than either AKT or MEK inhibition alone.

PI3K inhibitors cause rapid inhibition of ERK in breast cancer cells with HER2 amplification, but pERK levels rebound fairly quickly. Even so, this transient inhibition is required for significant induction of apoptosis by these drugs. We asked whether more complete and sustained inhibition of ERK might enhance induction of cell death by the PI3K inhibitor. We found that, in BT-474, SK-BR-3 or MDA-MB-361 cells, the addition of PD901 could further enhance the apoptotic effects of the PI3K inhibitor, as quantitated by sub-G1 DNA content (Fig. 6C). In BT-474 and MDA-MB-361 cells, MEK inhibition enhanced the induction of apoptosis caused by AKT inhibition alone, but the combination was not nearly as potent as PI3K inhibition alone. In SK-BR-3 cells, combined MEK and AKT inhibition appeared nearly equivalent to PI3K inhibition alone. These results suggest that, in some cells, inhibition of other non-AKT targets of PI3K contributes to induction of apoptosis, or that stronger MEK inhibition is required to fully activate apoptosis. Combined inhibition of MEK and PI3K caused more apoptosis than any of the other treatments in all three models.

We wished to determine whether these findings were relevant in vivo. For this purpose, we utilized the BT-474 model grown as xenografts in immunocompromised mice. Intravenous administration of BAY 80-6946 caused rapid (within 10 minutes) inhibition of PI3K activity, as measured by decreased phosphorylation of AKT S473 and T308, and of ERK phosphorylation (Fig. 7A). Both were sustained for at least 60 minutes. Induction of caspase-3 and caspase-7 cleavage was detectable within 20 minutes of drug administration and markedly increased at 45 and 60 minutes after dosing. This experiment was performed three separate times with similar results. Thus, BAY 80-6946 causes both rapid inhibition of ERK signaling and rapid induction of apoptosis in vivo.

We asked whether inhibition of ERK with PD901 enhanced the induction of apoptosis by the AKT inhibitor MK2206 in vivo. As reported in previous work, AKT inhibition induced moderate apoptosis in HER2-amplified breast cancer xenografts (ref. 8; Fig. 7B and Supplementary Fig. S7A). MEK inhibition with PD901 was associated with minimal caspase cleavage not noticeably different from that observed with vehicle controls, 5 and 7 hours after drug addition (Fig. 7B and Supplementary Fig. S7A). In contrast, combined inhibition of MEK and AKT synergized to cause marked induction of apoptosis.

BAY 80-6946 has an extremely short half-life in mice (t1/2 = 0.7 hours), and maximal inhibition of the target persists only for 4 hours (data not shown), so we determined whether its therapeutic efficacy required continuous dosing by infusion. In the BT-474 xenograft model, we compared the effects of pulsatile BAY 80-6946 treatment (14 mg/kg three times/wk) and continuous administration of BAY 80-6946 via a mini-pump (42 mg/kg/wk). Pulsatile administration of BAY 80-6946 suppressed tumor growth to a much greater extent than continuous dosing (Supplementary Fig. S7B). Thus, relatively brief inhibition of the pathway three times per week was sufficient to significantly inhibit tumor growth. We speculate that transient inhibition of PI3K was more effective because of more complete inhibition of the target for a
Figure 6. Rapid induction of apoptosis by PI3K inhibitor is dependent on its downregulation of pERK. **A**, BT-474 cells were left untreated (lane 1); treated with BAY 80-6946 (50 nmol/L) alone (lanes 2 and 3); BAY 80-6946 (50 nmol/L) and EGF (100 ng/mL) (lanes 4 and 5); BAY 80-6946 (50 nmol/L), EGF (100 ng/mL), and PD901 (50 nmol/L) (lanes 6 and 7); or PD901 (50 nmol/L) alone (lanes 8 and 9), and collected at indicated times. Immunoblots show greatest induction of cleaved caspase-3, cleaved caspase-7, and cleaved PARP when both pERK and pAKT are inhibited. **B**, BT-474 cells were treated with MK2206 (2 μmol/L) alone, PD901 (50 nmol/L) alone, or a combination of MK2206 (2 μmol/L) and PD901 (50 nmol/L) and collected at indicated times. Immunoblots show greatest induction of cleaved caspase-3 and cleaved caspase-7 by the combination of AKT and MEK inhibition. **C**, BT-474 cells (top), SK-BR-3 cells (middle), or MDA-MB-361 cells (bottom) were treated in triplicate with DMSO, MK2206 (2 μmol/L), PD901 (50 nmol/L), BAY 80-6946 (50 nmol/L), a combination of MK2206 (2 μmol/L) and PD901 (50 nmol/L), or a combination of BAY 80-6946 (50 nmol/L) and PD901 (50 nmol/L) and collected at 72 hours. Samples were analyzed for induction of apoptosis by FACS and results were reported as mean percent sub-G₁ fraction with SEs (n = 3/group).
Figure 7. Combined MEK and AKT inhibition improves antitumor efficacy in vivo. A, mice bearing BT-474 xenografts were treated with a single dose of BAY 80-6946 (14 mg/kg) and tumors were collected at indicated times after treatment. Immunoblots of tumor lysates demonstrate downregulation of pAKT and pERK as well as induction of cleaved caspase-3 and cleaved caspase-7. B, mice bearing BT-474 xenografts were treated with vehicle, a combination of MK2206 (100 mg/kg) and PD901 (5 mg/kg), or either agent alone, and tumors were collected at 5 hours after treatment. Immunoblots of tumor lysates demonstrate greatest induction of cleaved caspase-3 and cleaved caspase-7 with the combination of MK2206 and PD901. C, mice bearing BT-474 xenografts were randomized to (1) vehicle five times/week, (2) PD901 5 mg/kg five times/week, (3) MK2206 100 mg/kg five times/week, (4) BAY 80-6946 14 mg/kg three times/week, (5) combination of (2) and (3), or (6) combination of (2) and (4), and tumor size was measured by vernier caliper two times per week. The results were reported as mean tumor volume with SEs (n = 10/group). The inset excludes groups (1) and (2).

short time and limited relief of feedback and reactivation of upstream signaling.

Having established the pulsatile schedule and dosing for BAY 80-6946 in vivo, we compared it with AKT inhibition by MK2206 (5 times/week at 100 mg/kg) in the BT-474 breast cancer xenograft model (Fig. 7C). AKT inhibition slowed the growth of tumors, but they still grew significantly. In contrast, pulsatile PI3K inhibition caused initial tumor regression and significantly suppressed tumor growth. The effectiveness of intermittent administration of the PI3K inhibitor and its superior antitumor activity compared with AKT inhibition were confirmed in another HER2-amplified, PIK3CA-mutant breast cancer model, MDA-MB-361 (Supplementary Fig. S7C).

We hypothesized that the effectiveness of PI3K inhibition was due in part to its combined inhibition of ERK and AKT. As previously reported, MEK inhibition with PD901 (5 times/week at 5 mg/kg) had no effect on BT-474 tumor growth (Fig. 7C, ref. 21). However, the combined inhibition of MEK and AKT was clearly synergistic, as tumors regressed for approximately 10 days and then began to grow. Taken together, the data support the idea that induction of significant apoptosis in HER2+ tumors requires the inhibition of both AKT and MEK signaling that is achieved with PI3K inhibitors. Combining MEK and AKT inhibition with two separate drugs worked almost as well as PI3K inhibition in this model. However, combining MEK and PI3K inhibition (3 times/week of 14 mg/kg BAY 80-6946 plus 5 times/week of 5 mg/kg PD901) caused greater and more sustained tumor regression than the latter alone, suggesting that deeper and longer ERK pathway inhibition is required to maximize antitumor activity.
DISCUSSION

The PI3K signaling pathway is dysregulated in a large proportion of tumors, most commonly by activating mutations of PIK3CA, activation of RTKs such as HER2, and loss of activity of the PTEN and INPP4B tumor suppressors, that negatively regulate the pathway (4, 22). Despite the powerful transforming activity of these alterations, clinical activity of inhibitors of PI3K, AKT, and mTOR has been disappointing and significantly less than that obtained with inhibitors of other oncogene-activated pathways (e.g., BRAF, EGFR, and ALK; refs. 23–25). We and others have found that activation of the PI3K pathway causes feedback inhibition of receptor signaling (8–10, 14). PI3K pathway inhibitors relieve this feedback and reactivate receptor signaling. It has been posited that this reactivation attenuates the therapeutic effects of pathway inhibitors. Inhibition of mTOR has been shown to activate receptor signaling and reactivate PI3K–AKT (9, 10), whereas AKT inhibition inhibits AKT but still reactivates PI3K (8). These data predict that PI3K inhibitors would inhibit AKT–mTOR signaling and reactivate receptor signaling, but would inhibit, rather than reactivate, PI3K itself. In this article, we asked whether this difference would have biologic or therapeutic consequences. Our ability to pursue this question was dependent on determining the dose range over which selective PI3K inhibitors do not affect mTOR activity.

We compared the effects of selective inhibition of PI3K and AKT and found that they were significantly different. In HER2-amplified breast cancer cells, the effects of the drugs on AKT signaling and reactivation of RTKs are very similar. PI3K inhibition, however, causes a rapid and significant induction of apoptosis, whereas AKT inhibition does not. The differential induction of apoptosis induced by PI3K turns out to be due to inhibition of PI3K targets other than AKT–mTOR. Remarkably, inhibition of PI3K, but not AKT, leads to the rapid inhibition of RAS activity in these tumors, which is accompanied by inhibition of CRAF, MEK, and ERK phosphorylation. Thus, inhibiting PI3K causes the rapid inhibition of both AKT–mTOR and RAS–ERK signaling, whereas AKT inhibitors suppress only the former and, in fact, activate the latter. The effects of the PI3K inhibitor on the two pathways were observed in cultured cells and in vivo in tumor xenografts, suggesting their potential clinical significance.

In a large panel of tumor models, PI3K inhibitors were shown to inhibit AKT signaling in all cells and inhibit RAS–ERK signaling in most cells but not those harboring a mutant allele of RAS. To confirm that mutant RAS signals independently of PI3K, we induced mutant RAS expression in a model previously shown that the ERK and PI3K pathways converge on key targets that regulate cell survival and proliferation. These include the BH3 domain protein BAD (20), the regulator of cap-dependent translation 4E-BP1 (31), and BCL2 (32). In tumors with coexistent activation of both ERK and AKT signaling, both pathways must be inhibited to suppress these targets, inhibit tumor growth, and induce cell death. The transience of this phenomenon may provide a clue for understanding the complexity of regulation of RAS–ERK signaling by PI3K. Our previous data and those of others show that PI3K activation will downregulate receptor signaling.

The transient changes in RAS–ERK activation led us to wonder whether they were necessary for the rapid induction of apoptosis we observed in these cells. We and others had previously shown that MEK–ERK inhibition alone in these cells had little to no effect (21), so we speculated that the inhibition of both AKT and ERK was necessary for induction of apoptosis. We found that addition of EGF could prevent the downregulation of ERK (but not AKT) caused by the PI3K inhibitor and prevent apoptosis. Apoptosis could be restored in these cells by adding a selective inhibitor of MEK so that once again both AKT and ERK are downregulated. This then clarified the mechanism underlying the difference in induction of apoptosis by PI3K and AKT inhibitors. PI3K inhibitors downregulate both AKT and ERK, whereas AKT inhibitors downregulate AKT but relieve RTK feedback and activate PI3K and ERK. Indeed, we find that combining MEK and AKT inhibitors causes synergistic apoptosis, though it does not rise to the level induced by PI3K inhibition.

The finding that PI3K is upstream of wild-type RAS is surprising though not novel. Although PI3K is almost always thought of as an effector rather than an activator of RAS, there are several descriptions of the latter (26–30). In most of these, pretreatment with a drug that inhibits PI3K prevented or reduced ligand-induced activation of RAS and/or ERK. For instance, Wennstrom and Downward showed that when serum-starved COS7 cells were pretreated with LY294002 or wortmannin, induction of RAS–GTP after 5-minute stimulation with EGF was blunted (26). Similarly, pretreatment of cells with wortmannin blocked low-dose platelet-derived growth factor (PDGF) activation of ERK, but not when higher concentrations of PDGF were used or in cells with high levels of PDGF receptor (27). These findings are consistent with our data that EGF stimulation causes PI3K-independent activation of ERK in BT-474. It is not clear why the idea that PI3K is upstream of RAS has not been incorporated into standard models of signaling. It may be due to the complexity of the systems, the reliance on ligand activation of serum-starved cells and transfection studies, the use of less-specific drugs like LY294002 and wortmannin, and most likely, the absence of a defined biologic consequence of PI3K regulation of RAS activation.

We have now used selective compounds to show that PI3K is upstream of both RAS and AKT, that inhibition of PI3K downstream regulates both ERK signaling (transiently) and AKT–mTOR signaling (durably), and that the transient inhibition of ERK is necessary for the potent induction of apoptosis by these drugs. Our data strongly suggest that PI3K inhibitors induce a greater degree of cell death than AKT inhibitors because they inhibit ERK signaling. MEK inhibition by itself has no effect, so the question becomes why transient ERK inhibition synergizes with PI3K inhibition to cause cell death. We and others have previously shown that the ERK and PI3K pathways converge on key targets that regulate cell survival and proliferation. These include the BH3 domain protein BAD (20), the regulator of cap-dependent translation 4E-BP1 (31), and BCL2 (32). In tumors with coexistent activation of both ERK and AKT signaling, both pathways must be inhibited to suppress these targets, inhibit tumor growth, and induce cell death.

The transience of this phenomenon may provide a clue for understanding the complexity of regulation of RAS–ERK signaling by PI3K. Our previous data and those of others show that PI3K activation will downregulate receptor signaling...
and ERK signaling via AKT–mTOR-dependent feedback mechanisms (7, 8, 14). AKT or mTOR inhibitors relieve this feedback and activate ERK signaling (7). Our data here show that PI3K is also required to maintain tonic levels of RAS activation in tumors with wild-type RAS. Thus, PI3K activation has two opposing effects on RAS signaling: at modest levels of PI3K signaling, ERK output may integrate PI3K output and feedback; in tumors with dysregulated activation of AKT and mTOR, feedback may predominate and result in low levels of ERK. In this model, selective inhibition of PI3K will inhibit RAS directly but also relieve feedback inhibition of receptors that would ultimately lead to RAS activation. We believe that the former occurs more quickly than the latter and that this accounts for the initial decline and subsequent rebound in ERK phosphorylation. The model also accounts for why inhibition of ERK signaling has not, for the most part, been recognized as a prominent property of PI3K inhibitors. First, most inhibitors used in the past have had multiple other targets, including, prominently, mTOR, which would be expected to blunt or negate the phenomenon. Second, the effect is rapid and obscured by relief of feedback and other adaptations over time.

These results have important implications for the treatment of patients with PI3K-dependent tumors, especially those with HER2-dependent cancers. We show that PI3K inhibitors ought to be more effective than AKT inhibitors, if they are selective and can be administered at doses that effectively inhibit the pathway. Selective AKT inhibitors and mTOR inhibitors that can potently inhibit AKT–mTOR signaling are expected to activate ERK, via receptor and PI3K activation, and this might blunt their therapeutic effects.

Recently, treatment with more-selective PI3K inhibitors has led to greater therapeutic efficacy in lymphomas and in breast cancer with PI3K mutation or HER2 amplification. The ability of any PI3K inhibitor to inhibit signaling adequately is limited by physiologic toxicity. Moreover, attempts to combine MEK inhibitors with “dual specificity” PI3K or AKT inhibitors have been complicated by severe toxicity at modest doses of these drugs. The idea that the pathway must be inhibited continuously dominates the clinical development of these drugs. Our finding that transient inhibition of PI3K is effective in in vivo models suggests that periodic rather than continuous target inhibition is an alternative strategy that would allow adequate pathway inhibition without causing inordinate toxicity or chronic feedback reactivation of receptors. Thus, combining PI3K inhibitors, MEK inhibitors, and, perhaps, inhibitors of key reactivated RTKs and administering them at high dose on intermittent schedules may be a more effective therapeutic strategy for these tumors.

METHODS

Cell Lines

SKMEL cell lines were from A. Houghton (Memorial Sloan-Kettering Cancer Center, New York, NY). The 293T packaging cell line was from Clontech. LAM TSC2++ cell line was from E. Henske (Brigham and Women’s Hospital). All other cell lines were from the American Type Culture Collection (ATCC). BT-474, SK-BR-3, LAM TSC2++, UACC-893, HCC1954, MDA-MB-453, MDA-MB-361, MCF7, HCC1806, MDA-MB-468, and MDA-MB-468TR-PTEN were grown in Dulbecco’s Modified Eagle Medium (DMEM)-F12, T-47D, NCI-H292, NCI-H1650, CCRF-SB, U937, SU-DHL-4, SU-DHL-5, NCI-H1703, NCI-H661, and PC9 were grown in RPMI-1640 medium; BT-20 was grown in minimum essential medium; A549 was grown in F-12K medium; HCT116 was grown in McCoy’s medium; SK-MEL-30, SK-MEL-2, and 293T were grown in DMEM. All media were supplemented with 100 μg/mL penicillin, 100 μg/mL streptomycin, 4 mM/L glutamine, and 10% FBS. All cells were maintained at 37°C in 5% CO2. Breast cancer cell lines previously described as HER2-amplified (BT-474, SK-BR-3, UACC-893, HCC1954, MDA-MB-453, MDA-MB-361) were confirmed to overexpress HER2 by immunoblotting for HER2. Breast cancer cell lines that were previously described as expressing estrogen receptor (ER; MCF-7, T-47D, BT-474, MDA-MB-361) were confirmed to express ER by immunoblotting for ER. Lung cancer cell lines previously described to have mutations in EGFR (NCI-H1650, PC9) were validated by Sanger sequencing of EGFR. SK-MEL cell lines were validated by genetic fingerprinting. Lymphoma cell lines (CCRF-SB, U937, SU-DHL-4, SU-DHL-5) were obtained from ATCC less than 6 months before performing the experiments in this paper. Remaining cell lines were not independently validated in our laboratory.

RAS-GTP Assay

Cells were harvested on ice and lysed immediately in either Igepal lysis buffer (50 mmol/L Tris-HCl pH 7.5, 10 mmol/L MgCl2, 0.5 mol/L NaCl, 2% Igepal) or RAS-GTP Lysis Buffer (Pierce) before centrifugation at 16,000 g for 2 minutes at 4°C. Experiments with BT-474, SK-BR-3, and NCI-H292 were performed with both lysis buffers and yielded similar results. The supernatant was collected and an aliquot was removed for a BCA assay (Pierce) to determine protein concentration, whereas the rest of the lysate was snap-frozen using dry ice and ethanol. An equal amount of protein (500–700 μg) from each sample was loaded onto a column with purified GST-RAF1-RAS-Binding-Domain and glutathione agarose resin (Pierce), except for the negative control sample, which does not contain the purified GST1-RAF1-RAS-Binding-Domain. The mixture was incubated for 1 hour at 4°C before washing 5 times with Wash Buffer (25 mmol/L Tris-HCl pH 7.5, 30 mmol/L MgCl2, 40 mmol/L NaCl). Samples were eluted in 2× LDS Sample Buffer (diluted with water from 4× LDS Sample Buffer by Invitrogen) with 200 mmol/L dithiothreitol. Samples were subsequently electrophoresed on 4%–12% or 12% Bis-Tris mini gels (Invitrogen) and GTP-bound levels of total RAS or RAS isoforms were detected by immunoblotting.

Further details can be found in Supplementary Methods.

Disclaimer

The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Disclosure of Potential Conflicts of Interest

J. Baselga is a consultant/advisory board member of Novartis. N. Liu is a principal scientist at Bayer HealthCare. N. Rosen is a consultant/advisory board member of Novartis. No potential conflicts of interests were disclosed by the other authors.

One of the Editors-in-Chief of Cancer Discovery is an author of this article. In keeping with the AACR’s editorial policy, the paper was peer reviewed and an AACR journal editor not affiliated with Cancer Discovery rendered the decision concerning acceptability.

Authors’ Contributions

Conception and design: M. Will, Z. Yao, V. Rodrik-Outmezguine, X. Jiang, E. De Stanchina, J. Baselga, S. Chandralapaty, N. Rosen

Development of methodology: M. Will, A.C.R. Qin, Z. Yao, V. Rodrik-Outmezguine, E. De Stanchina, S. Chandralapaty, N. Rosen

Published OnlineFirst January 16, 2014; DOI: 10.1158/2159-8290.CD-13-0611
ERK Inhibition Is Required for Apoptosis by PI3K Inhibitor

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Will, Z. Yao, C. Schneider, E. De Stanchina, J. Baselga, N. Rosen

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Will, W. Toy, Z. Yao, X. Jiang, J. Baselga, S. Chandarlapaty, N. Rosen

Writing, review, and/or revision of the manuscript: M. Will, A.C.R. Qin, J. Baselga, N. Liu, S. Chandarlapaty, N. Rosen

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.C.R. Qin, X. Huang, P. Monian, N. Liu, N. Rosen

Study supervision: N. Liu

Acknowledgments

The authors thank D. Domingo for assistance with FACS, Qiong Bai for use of the doxycycline-inducible PTEN MDA-MB-468 model, E. Henske for the LAM TSC<sup>−/−</sup> cell line, and Alan Hall and Poulikos Poulikakos for helpful discussions.

Grant Support

This work is supported by NIH Program Grant 5PO1CA094060 (to N. Rosen), Arlene Taub and the Breast Cancer Research Foundation (to N. Rosen), Damon Runyon Cancer Research Foundation (to S. Chandarlapaty), and Jeffrey Gee Beene Cancer Research Center (to S. Chandarlapaty and N. Rosen). M. Will was supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH under award number T32GM07739 to the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program.

Received September 10, 2013; revised January 6, 2014; accepted January 8, 2014; published online First January 16, 2014.

REFERENCES


Downloaded from cancerc Discovery.aacrjournals.org on December 29, 2017. © 2014 American Association for Cancer Research.
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling

Marie Will, Alice Can Ran Qin, Weiyi Toy, et al.

Cancer Discovery Published OnlineFirst January 16, 2014.

Updated version Access the most recent version of this article at: doi:10.1158/2159-8290.CD-13-0611

Supplementary Material Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2014/01/14/2159-8290.CD-13-0611.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/early/2014/02/19/2159-8290.CD-13-0611. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.